CD274 and non-small cell lung carcinoma: Over the last decade, the treatment for non-small cell lung cancer (NSCLC) has improved by the use of immune checkpoint inhibitors (ICIs), especially inhibitors targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) [1].